Physician profile
Stephanie Patrick
NPI 1730642307
$2,449.01
in general payments reported to CMS, 2019-2025
9 companies · $2,207 in 2025
The $2,207 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $242 · 2025: $2,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497 · Travel and Lodging: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.50 |
| Travel and Lodging | $952.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,536.04 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $285.84 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $202.70 | 2024-2025 | Omnipod |
| Dexcom, INC. | $181.43 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $67.10 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $58.31 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $45.90 | 2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $42.64 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.05 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.